以往文献指出:改变1-溶肉瘤素或其外消旋体(Ⅰ)的结构(包括α氨基的酰化或使(Ⅰ)转变为各种肽类等),可以引起它的抗肿瘤性能发生显著的改变。Cytoxan(Ⅱ,或称 B_z-518)是另一种临床使用的重要烷基化剂,认为它是输送氮芥部分进入肿瘤的有效形式之一,因为用药后肿瘤组织中的磷酰胺酶量增加,故知它是选择性地在肿瘤部分释放烷基化基团的。 Previous literature indicates that altering the structure of 1-lysomycin or its racemate (I), including the acylation of α-amino groups or the conversion of (I) to various peptides, can cause its anti-tumor properties to occur Significant change. Cytoxan (II, or B_z-518) is another clinically important alkylating agent considered to be one of the most effective forms of delivery of the nitrogen mustard moiety to tumors as the amount of phosphoramidite in the tumor tissue increases , It is known that it selectively releases alkylated groups in the tumor portion.